research Evaluation of 3-Month Data for the Use of Erenumab for Chronic Migraine in Glasgow May 2022 in “Journal of Neurology Neurosurgery & Psychiatry” Erenumab significantly reduced migraine days or severity in most patients after 3 months.
research Use of Calcitonin Gene-Related Peptide Monoclonal Antibodies in Patients With Rosacea: An Exploratory Comparative Case Series May 2023 in “Journal of Investigative Dermatology” CGRP MAbs treatment for migraines may also improve rosacea symptoms, but more research is needed to confirm its effectiveness and safety.